ValiRx granted patent in Australia for VAL201 targeting cancer

ValiRx has been granted a patent for its lead therapeutic compound VAL201 for the treatment of breast, prostate, breast and ovarian cancer in Australia.

ValiRx has been granted a patent for its lead therapeutic compound VAL201 for the treatment of breast, prostate, breast and ovarian cancer in Australia.

The cancer diagnostics company said VAL201 has shown efficacy in prostate, breast and ovarian cancer as well as addressing endometriosis or hormone induced abnormal cell growth in women.

VAL201, which is currently progressing though clinical development, has been shown to reduce the abnormal endometrial growth, while leaving other hormone-induced activities working normally.

The original patent and technology covering VAL201 is licensed by ValiRx from Cancer Research Technology for use in androgen resistant cancer.

ValiRx has all rights to perform pre-clinical and clinical developments and obtaining regulatory approvals in all territories

"The granting of this latest patent means that ValiRx is able to add to the Company's intellectual property assets and extend its already extensive IP protection for this compound and its intended indications," said Chief Executive Satu Vainikka.

Shares rose 5.26% to 0.50p at 10:13 Thursday.

RD

Recommended

Broker safety – your questions answered
Investment strategy

Broker safety – your questions answered

Cris Sholto Heaton answers more of your questions about the safety of stockbroker accounts
25 Mar 2020
How demographics affects stock valuations
Investment strategy

How demographics affects stock valuations

New research suggests that stock and bond valuations are driven by the age of the population – at least in the US.
24 Feb 2020
Do you own shares in Sirius Minerals? Here’s what you need to do now
Stocks and shares

Do you own shares in Sirius Minerals? Here’s what you need to do now

Mining giant Anglo American has proposed a cash takeover of Yorkshire-based minnow Sirius Minerals. Unhappy shareholders must decide whether to accept…
20 Feb 2020
Why investors should be “cautiously bullish” for 2020
Stockmarkets

Why investors should be “cautiously bullish” for 2020

Analysts have been out in force making rosy predictions for stockmarkets in 2020, but while there is certainly a case for optimism, investors should r…
17 Jan 2020

Most Popular

The rising dollar is proving bad news for most other assets – will it last?
Investment strategy

The rising dollar is proving bad news for most other assets – will it last?

Precious metals, stocks and pretty much every other asset has taken a tumble as the US dollar strengthens. Dominic Frisby looks at how long this trend…
23 Sep 2020
The electric-car bubble could get an awful lot bigger from here
Renewables

The electric-car bubble could get an awful lot bigger from here

The switch to electric cars is driving a huge investment bubble. But that’s not necessarily a bad thing, says John Stepek. Fortunes will be made and l…
24 Sep 2020
Why you should stuff your end-of-pandemic portfolio with Chinese stocks
China stockmarkets

Why you should stuff your end-of-pandemic portfolio with Chinese stocks

For an end-of-pandemic portfolio, you need assets that can cope with today’s volatility. And that, says Merryn Somerset Webb, means Chinese stocks.
14 Sep 2020